Perspective of Targeting Cancer-Associated Fibroblasts in Melanoma
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Melanoma is known as an exceptionally aggressive and treatment-resistant human cancer. Although a great deal of progress has been made in the past decade, including the development of immunotherapy using immune checkpoint inhibitors and targeted therapy using BRAF, MEK or KIT inhibitors, treatment for unresectable stage III, stage IV, and recurrent melanoma is still challenging with limited response rate, severe side effects and poor prognosis, highlighting an urgent need for discovering and designing more effective approaches to conquer melanoma. Melanoma is not only driven by malignant melanocytes, but also by the altered communication between neoplastic cells and non-malignant cell populations, including fibroblasts, endothelial and inflammatory cells, in the tumor stroma. Infiltrated and surrounding fibroblasts, also known as cancer-associated fibroblasts (CAFs), exhibit both phenotypical and physiological differences compared to normal dermal fibroblasts. They acquire properties of myofibroblasts, remodel the extracellular matrix (ECM) and architecture of the diseased tissue and secrete chemical factors, which all together promote the transformation process by encouraging tumor growth, angiogenesis, inflammation and metastasis and contribute to drug resistance. A number of in vitro and in vivo experiments have shown that stromal fibroblasts promote melanoma cell proliferation and they have been targeted to suppress tumor growth effectively. Evidently, a combination therapy co-targeting tumor cells and stromal fibroblasts may provide promising strategies to improve therapeutic outcomes and overcome treatment resistance. A significant benefit of targeting CAFs is that the approach aims to create a tumor-resistant environment that inhibits growth of melanomas carrying different genetic mutations. However, the origin of CAFs and precise mechanisms by which CAFs contribute to melanoma progression and drug resistance remain poorly understood. In this review, we discuss the origin, activation and heterogeneity of CAFs in the melanoma tumor microenvironment and examine the contributions of stromal fibroblasts at different stages of melanoma development. We also highlight the recent progression in dissecting and characterizing how local fibroblasts become reprogrammed and build a dynamic yet optimal microenvironment for tumors to develop and metastasize. In addition, we review key developments in ongoing preclinical studies and clinical applications targeting CAFs and tumor-stroma interactions for melanoma treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kalluri, R., & Zeisberg, M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1877 · Cited by 4,538 · cited 3×
“forming growth factor-beta (TGF-β), for which fibroblasts are an important source, is known to suppress melanocyte and early stage melanoma cell cycle progression [60].”
BackgroundOrimo, A., Gupta, P. B., Sgroi, D. C., Arenzana-Seisdedos, F., Delaunay, T., Naeem, R., Carey, V. J., Richardson, A. L., & Weinberg, R. A. (2005) · Cell · doi:10.1016/j.cell.2005.02.034 · Cited by 3,759
The extracellular matrix: A dynamic niche in cancer progression
Lu, P., Weaver, V. M., & Werb, Z. (2012) · Journal of Cell Biology · doi:10.1083/jcb.201102147 · Cited by 3,024 · cited 1×
“CAFs produce a variety of ECM proteins such as laminins, fibronectin, tenascin C (TN-C), and fibrillar collagens, which are the structural components that make up connective tissue and contribute to the dense fibrous nature of solid tumors [94].”
BackgroundMechanisms of Cancer Drug Resistance
Gottesman, M. M. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.103929 · Cited by 2,643 · cited 1×
“Drug resistance in melanoma can be either pre-existent (intrinsic resistance) or induced by treatment (acquired resistance) [34, 35].”
BackgroundHyaluronan: from extracellular glue to pericellular cue
Toole, B. P. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1391 · Cited by 2,125 · cited 1×
“Hyaluronan is a large polysaccharide usually consisting of 2,000–25,000 disaccharides [70].”
BackgroundDrug Resistance and the Solid Tumor Microenvironment
Tredan, O., Galmarini, C. M., Patel, K., & Tannock, I. F. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm135 · Cited by 2,116 · cited 1×
“Heterogeneity of CAFs leads to gradients of nutrition, hypoxia and acidity in the tumor mass, all of which can reduce the sensitivity of tumor cells to drug treatment [129].”
BackgroundTumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
Straussman, R., Morikawa, T., Shee, K., Barzily-Rokni, M., Qian, Z. R., Du, J., Davis, A., Mongare, M. M., Gould, J., Frederick, D. T., et al. (2012) · Nature · doi:10.1038/nature11183 · Cited by 1,771 · cited 2×
“HGF secreted by CAFs results in activation of the HGF receptor MET and downstream MAPK and PI3K/AKT signaling pathways, which are responsible for the immediate resistance of BRAF-mutant melanoma to BRAF inhibitors [42].”
BackgroundCarcinoma-associated fibroblasts stimulate tumor progression of initiated human epithelium
Olumi, A., Grossfeld, G., Hayward, S., Carroll, P., Cunha, G., Hein, P., & Tlsty, T. (2000) · Breast Cancer Research · doi:10.1186/bcr138 · Cited by 1,463
Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy
Shi, H., Hugo, W., Kong, X., Hong, A., Koya, R. C., Moriceau, G., Chodon, T., Guo, R., Johnson, D. B., Dahlman, K. B., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0642 · Cited by 982
Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance
Das Thakur, M., Salangsang, F., Landman, A. S., Sellers, W. R., Pryer, N. K., Levesque, M. P., Dummer, R., McMahon, M., & Stuart, D. D. (2013) · Nature · doi:10.1038/nature11814 · Cited by 730
Cited by
Carcinoma-associated fibroblasts: orchestrating the composition of malignancy
Gascard, P., & Tlsty, T. D. (2016) · Genes & Development · doi:10.1101/gad.279737.116 · Cited by 732
The myofibroblast, a key cell in normal and pathological tissue repair
Darby, I. A., Zakuan, N., Billet, F., & Desmoulière, A. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-2110-0 · Cited by 328
“Hence, anticancer strategies are now conceivable with the aim being to specifically target myofibroblasts in the tumour stroma [136, 137].”
Targeting the cancer-associated fibroblasts as a treatment in triple-negative breast cancer
Takai, K., Le, A., Weaver, V. M., & Werb, Z. (2016) · Oncotarget · doi:10.18632/oncotarget.12658 · Cited by 207
Chen, B., Dai, W., Mei, D., Liu, T., Li, S., He, B., He, B., Yuan, L., Zhang, H., Wang, X., et al. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.09.014 · Cited by 142
Ayuso, J. M., Sadangi, S., Lares, M., Rehman, S., Humayun, M., Denecke, K. M., Skala, M. C., Beebe, D. J., & Setaluri, V. (2021) · Lab on a Chip · doi:10.1039/d0lc00988a · Cited by 39
Metadata
- Authors
- Zhou, L., Yang, K., Andl, T., Wickett, R. R., & Zhang, Y.
- Venue
- Journal of Cancer
- Publisher
- Ivyspring International Publisher
- Published
- 2015
- Volume
- 6
- Issue
- 8
- Pages
- 717-726
- ISSN
- 1837-9664 (ISSN-L)
- OpenAlex
- W969758129
- Cited by
- 116
- References
- 18
- FWCI
- 4.89
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Perspective of Targeting Cancer-Associated Fibroblasts in Melanoma. https://app.cochat.ai/papers/10.7150/jca.10865
- The paper
- Zhou, L., Yang, K., Andl, T., Wickett, R. R., & Zhang, Y. (2015). Perspective of Targeting Cancer-Associated Fibroblasts in Melanoma. Journal of Cancer. https://doi.org/10.7150/jca.10865
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.